News

Cronos Brand Spinach® Celebrates Summer with New Launches

TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc.’s (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) Spinach® brand…

1 year ago

Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product

TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF),…

1 year ago

ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set…

1 year ago

STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines

Press Release STALICLA’s precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with…

1 year ago

OraSure Technologies Supports National HIV Testing Day

BETHLEHEM, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic…

1 year ago

Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery

- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide…

1 year ago

Tilray Brands Announces Runner’s High Brewing Company – Its New Brand of Premium Non-Alcoholic Brews

Runner’s High Brewing Taps into the Social Running CommunityNEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray…

1 year ago

Expanded Access to XHANCE with Addition to National Commercial Formularies

YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose…

1 year ago

Fortrea Launches AI Innovation Studio to Galvanize Technology and Human Solutions to Improve Clinical Trial Delivery

DURHAM, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced…

1 year ago

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using…

1 year ago